Kenneth Zuerblis
Director/Board Member chez RESVERLOGIX CORP.
Fortune : 44 077 $ au 31/03/2024
Postes actifs de Kenneth Zuerblis
Sociétés | Poste | Début | Fin |
---|---|---|---|
RESVERLOGIX CORP. | Director/Board Member | 29/09/2010 | - |
Independent Dir/Board Member | 29/09/2010 | - | |
ZENITH CAPITAL CORP. | Director/Board Member | 10/04/2013 | - |
Independent Dir/Board Member | 10/04/2013 | - | |
Lirum Therapeutics, Inc.
Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | Director/Board Member | 01/05/2023 | - |
Historique de carrière de Kenneth Zuerblis
Anciens postes connus de Kenneth Zuerblis
Sociétés | Poste | Début | Fin |
---|---|---|---|
STEMLINE THERAPEUTICS, INC. | Director/Board Member | 01/03/2012 | 10/06/2020 |
SAVIENT PHARMACEUTICALS INC | Director of Finance/CFO | 12/09/2011 | 01/05/2012 |
Treasurer | 12/09/2011 | 01/05/2012 | |
IMMUNOMEDICS, INC. | Director/Board Member | 11/02/2010 | 08/03/2012 |
Independent Dir/Board Member | 10/02/2010 | 08/03/2012 | |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Director of Finance/CFO | 01/01/2009 | 01/01/2009 |
XTL BIOPHARMACEUTICALS LTD. | Director/Board Member | 01/01/2009 | 01/01/2009 |
ENZON PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 01/01/1991 | 01/01/1994 |
Director of Finance/CFO | 01/01/1994 | 01/01/2005 | |
░░░░ ░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░ ░░░░░░ ░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
Formation de Kenneth Zuerblis
Seton Hall University | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 10 |
Canada | 2 |
2 |
Opérationnelle
Director/Board Member | 7 |
Director of Finance/CFO | 3 |
Independent Dir/Board Member | 3 |
Sectorielle
Health Technology | 9 |
Commercial Services | 3 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 4 |
---|---|
ENZON PHARMACEUTICALS, INC. | Health Technology |
RESVERLOGIX CORP. | Health Technology |
XTL BIOPHARMACEUTICALS LTD. | Health Technology |
Health Technology |
Entreprise privées | 7 |
---|---|
Savient Pharmaceuticals, Inc.
Savient Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Savient Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company, which develops, manufactures and markets pharmaceutical products. The company focuses on developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients who do not respond to conventional therapy. It also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. The company was founded in 1980 is headquartered in East Brunswick, NJ. | Health Technology |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Health Technology |
Immunomedics, Inc.
Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
Zenith Capital Corp. (Alberta) | |
KPMG LLP
KPMG LLP Miscellaneous Commercial ServicesCommercial Services KPMG LLP engages in the provision of audit, tax, and advisory services. It serves the banking and capital markets, building, construction and real estate, consumer and retail, energy, natural resources and chemicals, financial services, government and public sector, healthcare and life sciences, industrial manufacturing, insurance, media and entertainment, private equity, technology, telecommunications, and venture capital industries. The company was founded in 1987 and is headquartered in New York, NY. | Commercial Services |
New Jersey Technology Council
New Jersey Technology Council Miscellaneous Commercial ServicesCommercial Services New Jersey Technology Council provides business development, education and advocacy services. It serves communications, e-business, multimedia, consumer technologies, manufacturing, engineering and energy sectors. The company was founded in 1996 and is headquartered in New Brunswick, NJ. | Commercial Services |
- Bourse
- Insiders
- Kenneth Zuerblis
- Expérience